Synthetic genes company raises £7.8m after new contract wins
Camena Bioscience, a Cambridge-based company which provides synthetic genes to the pharmaceutical and biotechnology industries, has completed a £7.8m ($10m) Series A funding round led by Mercia Ventures. The new funding will be used to scale operations and continue development of its pioneering DNA synthesis platform, gSynth. Camena is the first company to offer this